COMMENTARY

Analysis of research findings and other key developments in oncology from leading experts and clinicians practicing in diverse settings.

Page 1 of 16

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Accumulating Data Support Bevacizumab Use for Recurrent High-Grade Glioma

Patrick Morris, MD, 2012 May 16

IntroductionMost primary brain tumors arise from the support cells of the brain or glia, rather than from neurons. Broadly speaking, these rare tumors, or gliomas, are characterized both by their cell...

Perspective - Oncologic Darwinism

Matthew RG Taylor, MD, PhD, 2012 May 9, Elsevier Global Medical News

Abstract When I was in medical school in the early 1990s, the basic model for cancer was that a single cell harboring a mutation, often caused by exposure to tobacco or radiation, was the inciting event...

Point/Counterpoint: Is Marijuana Medicinal?

Donald I. Abrams, MD, Jodie Trafton, PhD, 2012 Apr 24, Elsevier Global Medical News

POINT: Cannabis can relieve neuropathic painAs an oncologist, I treat cancer patients who have nausea, vomiting, weight loss, pain with and without opioids, insomnia, and depression. With cannabis, I can...

PCI-32765 Is One of the Most Exciting Drugs Around

Susan O’Brien, MD, 2012 Mar 19

Susan M. O'Brien, MD, is Ashbel Smith Professor, Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center in Houston. In this interview, Dr. O’Brien discusses...

Endpoints Explained—Part I

Daniel J. Sargent, PhD, 2012 Mar 14

Daniel J. Sargent, PhD, is the Ralph S. and Beverly E. Caulkins Professor of Cancer Research at the Mayo Clinic Cancer Center in Rochester, Minnesota, and Group Statistician for the Alliance for Clinical...

MDV3100 Extends Survival in Men With Late-Stage Prostate Cancer—The AFFIRM Trial

Howard Scher, MD, 2012 Feb 29

In this commentary, Dr. Scher discusses his research on a novel androgen receptor signaling inhibitor, MDV3100, which was shown to improve survival in a post-chemotherapy population of men with progressive...

Update on Emerging Techniques in Breast Imaging

Maxine Jochelson, MD, 2012 Feb 22

Maxine S. Jochelson, MD, Director of Radiology, Breast and Imaging Center, at Memorial Sloan-Kettering Cancer Center in New York discusses emerging techniques in breast imaging and their potential to improve...

Dr. Andre Goy: The B-cell Inhibitors Will be Game-Changing in B-cell Lymphoma and CLL

Andre Goy, MD, 2012 Feb 8

To mark 2011, we have asked our distinguished OncologySTAT Advisory Board Members to choose their top story of the year. In this commentary, Dr. Andre Goy discusses his choice for 2011 in lymphoma. The...

Point/Counterpoint: What is the First-line Treatment of Choice for Metastatic BRAF-mutant Melanoma?

M Sznol, JA Sosman, 2011 Nov 14, Elsevier Global Medical News

Consider immunotherapy as first-line treatment.Application of immunotherapy is becoming increasingly more sophisticated as we learn to control the many signals that activate and deactivate T cells. We...

Key GI and Lung Studies From The European Multidisciplinary Cancer Congress, Stockholm

Jean-Yves Douillard, MD, 2011 Oct 11

Several interesting studies were presented. The most interesting for me—even though I am familiar with the data because they were presented at the World Congress on Gastrointestinal Cancer in Barcelona...

« start ‹ previous ... 1 2 3 4 5 ... next › end »

Page 1 of 16

Comment Print page RSS feeds

Editors' Choice

Everolimus Plus Tamoxifen Improves Survival in Metastatic Breast Cancer

Meet Our Experts

Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.

View the boards ›